24 completed, 13 unknown, 5 terminated, 1 active not recruiting. 13 Phase 3, 11 Not applicable, 9 Phase 2, 5 Phase 4, 4 Phase 1.
Follow Branch Retinal Vein Occlusion: new trials by email Literature Review of Branch Retinal Vein Occlusion trials Research Report on Branch Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss 601 1.25mg, ranibizumab 0.5mg - Branch Retinal Vein Occlusion | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 351 | 2022-12-27 | 2025-12-18 |
| A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products Faricimab, Port Delivery System with Ranibizumab - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Active not recruiting | Hoffmann-La Roche | 6000 | 2022-11-21 | 2026-10-02 | |
| EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) IRX-101, Control - Diabetic Macular Edema, Branch Retinal Vein Occlusion | Phase 3 | Terminated | iRenix Medical, Inc. | 5 | 2021-11-15 | 2022-05-24 |
| Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Celecoxib - Macula Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 3 | 2021-03-05 | 2023-11-24 |
| A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Faricimab, Aflibercept, Sham Procedure - Macular Edema, Branch Retinal Vein Occlusion | Phase 3 | Completed | Hoffmann-La Roche | 553 | 2021-03-02 | 2024-08-06 |
| 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) 601 1.25mg, Ranibizuman 0.5 mg - Branch Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-28 | 2025-06-27 |
| Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion aflibercept (2mg/0.05ml) - Branch Retinal Vein Occlusion | Not applicable | Completed | Al-Azhar University | 60 | 2020-12-01 | 2023-11-24 |
| Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Bevacizumab Ophthalmic - Branch Retinal Vein Occlusion | Not applicable | Unknown | He Eye Hospital | 100 | 2020-10-31 | 2020-10-26 |
| Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Dexamethasone - Macular Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 2 | 2019-09-01 | 2023-11-24 |
| Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection - Branch Retinal Vein Occlusion | Phase 3 | Terminated | Novartis Pharmaceuticals | 450 | 2019-07-02 | 2023-01-30 |
| Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage anti-VEGF, fan-shaped photocoagulation - Anti-VEGF, Branch Retinal Vein Occlusion | Not applicable | Unknown | Wenzhou Medical University | 100 | 2018-10-01 | 2018-08-17 |
| Navigated Laser In Branch Retinal Vein Occlusion Study Aflibercept Injection [Eylea], Navigated laser photocoagulation - Branch Retinal Vein Occlusion, Macular Edema | Not applicable | Completed | Odense University Hospital | 47 | 2018-08-10 | 2022-04-20 |
| Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO Ranibizumab combined macular laser, Ranibizumab - Branch Retinal Vein Occlusion, Ranibizumab | Not applicable | Completed | Beijing Hospital | 80 | 2017-02-14 | 2022-12-28 |
| Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion Conbercept ophthalmic injection, sham/Conbercept ophthalmic injection - Branch Retinal Vein Occlusion, Macular Edema | Phase 3 | Completed | Chengdu Kanghong Biotech Co., Ltd. | 255 | 2016-04-13 | 2022-07-15 |
| Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Aflibercept - Retinal Vein Occlusion, Diabetic Macular Edema | Phase 4 | Completed | Justis Ehlers | 31 | 2015-08-18 | 2021-05-12 |
| Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects Dynamic Vessel Analyzer, Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT) - Branch Retinal Vein Occlusion, Retinal Blood Flow | Not applicable | Unknown | Medical University of Vienna | 60 | 2015-08-01 | 2022-04-07 |
| Retinal Sensitivity in BRVO After Anti-VEGF Therapy Ranibizumab, Ranibizumab and laser - Branch Retinal Vein Occlusion | Phase 4 | Unknown | Fukushima Medical University | 50 | 2015-06-01 | 2015-08-19 |
| Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study Free Eye Screenings, Enhanced Intervention, Usual Care - Glaucoma, Glaucoma Suspect | Not applicable | Completed | Wills Eye | 906 | 2014-09-01 | 2022-08-22 |
| Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Ranibizumab - Branch Retinal Vein Occlusion | Phase 4 | Completed | Nagoya City University | 27 | 2014-01-01 | 2019-08-20 |
| Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion ranibizumab - Macular Edema, Branch Retinal Vein Occlusion | Not applicable | Unknown | Tokyo Medical University | 100 | 2013-12-01 | 2014-06-23 |
Showing 20 of 43. Sign in to see all of them.
Retinal Vein Occlusion (43) · Macular Edema (21) · Vision Disorders (5) · Macular Degeneration (4) · Diabetic Retinopathy (2) · Epiretinal Membrane (2) · Glaucoma (2) · Retinal Artery Occlusion (2) · Uveitis, Intermediate (2) · Cataract (1) · Choroidal Neovascularization (1) · Eye Diseases (1) · Glaucoma, Angle-Closure (1) · Neovascularization, Pathologic (1) · Ocular Hypertension (1)
Cardiovascular Diseases (43) · Embolism and Thrombosis (43) · Retinal Diseases (43) · Vascular Diseases (43) · Venous Thrombosis (43) · Eye Diseases (42) · Thrombosis (42) · Retinal Degeneration (24) · Macular Degeneration (20) · Pathological Conditions, Signs and Symptoms (7) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Sensation Disorders (5) · Signs and Symptoms (5) · Metaplasia (3)
Ranibizumab (15) · aflibercept (5) · Bevacizumab (3) · Dexamethasone (2) · Lasers (2) · Triamcinolone (2) · faricimab (2) · salicylhydroxamic acid (2) · Atorvastatin (1) · Calcium Dobesilate (1) · Niacin (1) · Predictive Value of Tests (1) · Standard of Care (1) · Tomography, Optical Coherence (1) · Triamcinolone Acetonide (1)
Novartis Pharmaceuticals (3) · Hoffmann-La Roche (2) · Medical University of Vienna (2) · Shahid Beheshti University of Medical Sciences (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · Targeted Therapy Technologies, LLC (2) · University of Toronto (2) · Al-Azhar University (1) · Beijing Hospital (1) · Chengdu Kanghong Biotech Co., Ltd. (1) · Federal University of Rio Grande do Sul (1) · Fukushima Medical University (1) · Hanscom, Thomas, M.D. (1) · He Eye Hospital (1) · Helse Stavanger HF (1)
United States (15) · Japan (8) · China (7) · South Korea (7) · Canada (6) · Czechia (5) · Germany (5) · United Kingdom (5) · Austria (4) · Denmark (4) · France (4) · Italy (4) · Poland (4) · Spain (4) · Australia (3)
Se Woong Kang, M.D. (2) · Theodore Leng, MD (2) · Alireza Ramezani, MD (1) · Baruch D Kuppermann,, M.D., Ph.D. (1) · Chris Hudson, OD, PhD (1) · Daniel Lavinsky, MD, PhD (1) · David Wong, MD (1) · Dong Ho Park, M.D. (1) · Emmanuel E Pazo (1) · Hidetaka Noma, MD (1) · Hong Dai, Bachelor (1)
PMID 32633861, PMID 36912792, PMID 27039022, PMID 28673747, PMID 28807635, PMID 30770354, PMID 31757691, PMID 32560639, PMID 33370517, PMID 34014814, PMID 34934034, PMID 37381014, PMID 38280653, PMID 40886069, PMID 42753135, PMID 42778337
2018 (1)